BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25087049)

  • 1. Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists.
    Cheng MF; Ou LC; Chen SC; Chang WT; Law PY; Loh HH; Chao YS; Shih C; Yeh SH; Ueng SH
    Bioorg Med Chem; 2014 Sep; 22(17):4694-703. PubMed ID: 25087049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists.
    Chen SR; Ke YY; Yeh TK; Lin SY; Ou LC; Chen SC; Chang WT; Chang HF; Wu ZH; Hsieh CC; Law PY; Loh HH; Shih C; Lai YK; Yeh SH; Ueng SH
    Eur J Med Chem; 2017 Jan; 126():202-217. PubMed ID: 27776274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats.
    Helmstetter FJ; Bellgowan PS; Poore LH
    J Pharmacol Exp Ther; 1995 Oct; 275(1):381-8. PubMed ID: 7562575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
    Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
    Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one: A Novel Opioid Receptor Agonist with Less Accompanying Gastrointestinal Dysfunction than Morphine.
    Chao PK; Ueng SH; Ou LC; Yeh TK; Chang WT; Chang HF; Chen SC; Tao PL; Law PY; Loh HH; Cheng MF; Chuang JY; Chen CT; Shih C; Yeh SH
    Anesthesiology; 2017 May; 126(5):952-966. PubMed ID: 28212204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
    Gallantine EL; Meert TF
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.
    Kaski SW; White AN; Gross JD; Siderovski DP
    Anesth Analg; 2021 Feb; 132(2):406-419. PubMed ID: 33332902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.
    Wang ZL; Pan JX; Song JJ; Tang HH; Yu HP; Li XH; Li N; Zhang T; Zhang R; Zhang MN; Xu B; Fang Q; Wang R
    J Med Chem; 2016 Nov; 59(22):10198-10208. PubMed ID: 27798836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists.
    Turnaturi R; Parenti C; Prezzavento O; Marrazzo A; Pallaki P; Georgoussi Z; Amata E; Pasquinucci L
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29547588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, stereospecific characterization and peripheral modification of 1-(pyrrolidin-1-ylmethyl)-2-[(6-chloro-3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinolines as novel selective κ opioid receptor agonists.
    Gan ZJ; Wang YH; Xu YG; Guo T; Wang J; Song Q; Xu XJ; Hu SY; Wang YJ; Wang DC; Sun DZ; Zhang D; Xi T; Li HD; Zhang HB; Hang TJ; Lu HG; Liu JG
    Org Biomol Chem; 2015 May; 13(20):5656-73. PubMed ID: 25895552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
    Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
    Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.
    Chen XT; Pitis P; Liu G; Yuan C; Gotchev D; Cowan CL; Rominger DH; Koblish M; Dewire SM; Crombie AL; Violin JD; Yamashita DS
    J Med Chem; 2013 Oct; 56(20):8019-31. PubMed ID: 24063433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of κ Opioid Receptor Agonists by Focusing on Phenyl Substituents of 4-Dimethylamino-3-phenylpiperidine Derivatives: Structure-Activity Relationship Study of Matrine Type Alkaloids.
    Teramoto H; Yamauchi T; Sasaki S; Higashiyama K
    Chem Pharm Bull (Tokyo); 2016; 64(5):420-31. PubMed ID: 27150474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
    Huang H; Wang W; Xu X; Zhu C; Wang Y; Liu J; Li W; Fu W
    Eur J Med Chem; 2020 Mar; 189():112070. PubMed ID: 31982651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
    Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
    Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.